Renal Cell Carcinoma News

FDA grants priority review to Cabometyx for advanced renal cell carcinoma - Healio



Wolcott Daily
 
FDA grants priority review to Cabometyx for advanced renal cell carcinoma 
Healio
The FDA granted priority review to cabozantinib for first-line treatment of advanced renal cell carcinoma, according to the drug's manufacturer. A supplemental new drug application included data from the randomized, open-label, active-controlled phase ...
FDA Grants Priority Review to Frontline Cabozantinib in RCC OncLive
Exelixis shares surge 19% premarket after FDA grants priority review to kidney cancer drug MarketWatch
Exelixis Pops as FDA Gives Kidney Cancer Drug Priority Review -- Biotech Movers TheStreet.com
Motley Fool  -Markets Insider  -Nasdaq  -Zacks Investment Research 
all 158 news articles » 


Gene assay predicts renal cell carcinoma relapse - Healio



Gene assay predicts renal cell carcinoma relapse 
Healio
CHICAGO ? The Recurrence Score, a tool used to predict risk of relapse in renal cell carcinoma, appears effective in high-risk disease, according to an analysis of the S-TRAC trial presented at the ASCO Annual Meeting. ?Adjuvant therapy with sunitinib ...

 


RCC Subtypes Affect Post-Surgery Cancer-Related Mortality Risk - Renal and Urology News



Renal and Urology News
 
RCC Subtypes Affect Post-Surgery Cancer-Related Mortality Risk 
Renal and Urology News
Patients with papillary versus clear cell renal cell carcinoma have a 24% decreased risk of dying from their cancer. Cancer-specific mortality among patients who undergo surgery for non-metastatic renal cell carcinoma (RCC) vary according to histologic ...

 


Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy - Dove Medical Press



Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy 
Dove Medical Press
Abstract: Since 2005, the approved first-line treatment of metastatic renal cell carcinoma consists in tyrosine kinase inhibitors (TKIs) targeting the vascular endothelial growth factor receptors (VEGFRs). Axitinib is an oral second-generation TKI and ...

 


Immunological classification of renal cell carcinoma patients based on phenotypic analysis of immune check-point ... - UroToday



Immunological classification of renal cell carcinoma patients based on phenotypic analysis of immune check-point ... 
UroToday
We extracted 109 sets of tumour tissue-infiltrating lymphocytes from 80 patients who underwent surgical resection of renal cell carcinoma, of which 44 tumour tissue-infiltrating lymphocytes were multiply extracted from 15 patients. Each tumour tissue ...

 


2017 Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/ 58N or Renal Cell ... - Medgadget (blog)



2017 Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/ 58N or Renal Cell ... 
Medgadget (blog)
The Global Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/ 58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or EC 4. 2. 1. 1) report has been prepared keeping in mind the need of the customers ...

 


FDA Grants Priority Review for Exelixis' RCC Drug Cabomteyx ... - Nasdaq



FDA Grants Priority Review for Exelixis' RCC Drug Cabomteyx ... 
Nasdaq
Exelixis, Inc.EXEL announced that the FDA has granted priority review to its supplemental New Drug Application (sNDA) for Cabomteyx. The sNDA seeks.
Company News For Oct 17, 2017 - October 17, 2017 - Zacks.com Zacks.com
UPDATE: Exelixis (EXEL) PT Raised to $33 at Needham & Company StreetInsider.com

all 3 news articles » 


How immunotherapy is transforming cancer treatment and patient care - Baylor College of Medicine News (press release) (blog)



Baylor College of Medicine News (press release) (blog)
 
How immunotherapy is transforming cancer treatment and patient care 
Baylor College of Medicine News (press release) (blog)
Dr. Andrew Sikora, co-director of the head and neck cancer program at Baylor, explains what immunotherapy does to the body to treat cancer.

and more » 


Seventh Peer Reviewed Publication on Angle's Parsortix(TM) System - Marketwired (press release)



Proactive Investors UK
 
Seventh Peer Reviewed Publication on Angle's Parsortix(TM) System 
Marketwired (press release)
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, today announces that its Parsortix? system is the subject of a peer-reviewed ...
ANGLE PLC 's Parsortix liquid biopsy top in kidney cancer study Proactive Investors UK
Angle's Parsortix system is strongest performer in German study DIGITALLOOK

all 4 news articles » 


FDA advisory committee split on opinion of adjuvant Sutent for renal cell carcinoma - Healio



FDA advisory committee split on opinion of adjuvant Sutent for renal cell carcinoma 
Healio
The FDA's Oncologic Drug Advisory Committee today voted 6-6 on whether the risk-benefit profile of sunitinib malate is acceptable for the adjuvant treatment of patients with a high-risk for recurrent renal cell carcinoma following nephrectomy. The ...
FDA Panel Splits on Adjuvant Sunitinib in High-Risk RCC OncLive
Pfizer Announces Outcome of FDA Advisory Committee Meeting for SUTENT® in Patients at High Risk of Recurrent ... Business Wire (press release)

all 3 news articles »